We queried the co-occurrence of NSP3 (SH2D3C) alterations with other genetic alterations and found that NSP3 (SH2D3C) alteration is inversely associated with Epidermal Growth Factor Receptor (EGFR) alterations in lung cancer, i.e., lung cancer patients with NSP3 (SH2D3C) alteration are devoid of EGFR alterations (Figure 2G). This evidence concerns the gene SH2D3C and lung carcinoma.